Publication: The impact of smoking on response to tumor necrosis factor-α inhibitor treatment in patients with ankylosing spondylitis
dc.contributor.author | Tuğsal, Handan Yarkan | |
dc.contributor.author | Kenar, Gökce | |
dc.contributor.author | Can, Gerçek | |
dc.contributor.author | Çapar, Sedat | |
dc.contributor.author | Zengin, Berrin | |
dc.contributor.author | Akar, Servet | |
dc.contributor.author | Şenel, Soner | |
dc.contributor.author | Koca, Süleyman Serdar | |
dc.contributor.author | Göker, Berna | |
dc.contributor.author | Yazıcı, Ayten | |
dc.contributor.author | Inanç, Nevsun | |
dc.contributor.author | Ellidokuz, Hülya | |
dc.contributor.author | Akkoç, Nurullah | |
dc.contributor.author | Önen, Fatoş | |
dc.contributor.buuauthor | Dalkilic, Ediz | |
dc.contributor.buuauthor | DALKILIÇ, HÜSEYİN EDİZ | |
dc.contributor.department | Bursa Uludağ Üniversitesi/Tıp Fakültesi/Romatoloji Anabilim Dalı. | |
dc.contributor.researcherid | JHC-5173-2023 | |
dc.date.accessioned | 2024-11-29T12:38:29Z | |
dc.date.available | 2024-11-29T12:38:29Z | |
dc.date.issued | 2023-01-01 | |
dc.description.abstract | Background/aim: To investigate the impact of smoking on disease activity, treatment retention, and response in patients with ankylosing spondylitis (AS) treated with their first tumor necrosis factor-alpha inhibitor (TNFi).Materials and methods: AS patients who started their first TNFi treatment for the active axial disease (BASDAI >= 4) from TURKBIO Registry were included. Treatment response of smoker (current and ex-smokers) and nonsmoker (never smoker) patients were primarily evaluated as achievement of BASDAI50 or improvement in BASDAI at least 20 mm at 3 months and 6 months compared to baseline.Results: There were 322 patients with AS (60% male, 59% smoker, mean age: 38.3 years). The median follow-up time was 2.8 years (Q1-Q3: 1.3-3.8), and disease duration was 3.5 years (Q1-Q3: 0.7-8.2). Smokers had male predominance (p < 0.001), lower ESR (p = 0.03), higher BASDAI (p = 0.02), BASFI (p = 0.05), HAQ-AS (p = 0.007), and ASDAS-CRP (p = 0.04) compared with nonsmokers at baseline. In the multivariate analysis, male gender [OR 2.7 (95%CI 1.4-5), p = 0.002], and concomitant conventional synthetic disease-modifying antirheumatic drug use [OR 2.4 (95%CI 1.1-5.2), p = 0.03] were associated with better treatment response. There was an association of male gender [HR 2.4 (95%CI 1.6-3.7), p < 0.001], older age (>= 30years) [HR 1.8 (95%CI 1.1-2.8), p = 0.01], and response to treatment [HR 1.8 (95%CI 1.2-2.9), p = 0.008] with better treatment retention. No impact of smoking status was found on treatment retention and response in univariate and multivariate analyses.Conclusion: This study suggested that smoking was associated with poorer patient-reported outcomes in biologic naive AS patients initiating their first TNFi treatment, but it had no impact on the TNFi treatment response and retention rate. | |
dc.identifier.doi | 10.55730/1300-0144.5661 | |
dc.identifier.endpage | 978 | |
dc.identifier.issn | 1300-0144 | |
dc.identifier.issue | 4 | |
dc.identifier.startpage | 970 | |
dc.identifier.uri | https://doi.org/10.55730/1300-0144.5661 | |
dc.identifier.uri | https://hdl.handle.net/11452/48725 | |
dc.identifier.volume | 53 | |
dc.identifier.wos | 001166710900014 | |
dc.indexed.wos | WOS.SCI | |
dc.language.iso | en | |
dc.publisher | Tubitak Scientific & Technological Research Council Turkey | |
dc.relation.journal | Turkish Journal Of Medical Sciences | |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | |
dc.rights | info:eu-repo/semantics/closedAccess | |
dc.subject | Quality-of-life | |
dc.subject | Activity score asdas | |
dc.subject | Anti-tnf therapy | |
dc.subject | Disease-activity | |
dc.subject | Axial spondyloarthritis | |
dc.subject | Cigarette-smoking | |
dc.subject | Functional ability | |
dc.subject | Structural damage | |
dc.subject | Progression | |
dc.subject | Smokers | |
dc.subject | Ankylosing spondylitis | |
dc.subject | Smoking | |
dc.subject | Tumor necrosis factor-alpha inhibitor | |
dc.subject | Treatment response | |
dc.subject | Registry | |
dc.subject | Science & technology | |
dc.subject | Life sciences & biomedicine | |
dc.subject | Medicine, general & internal | |
dc.subject | General & internal medicine | |
dc.title | The impact of smoking on response to tumor necrosis factor-α inhibitor treatment in patients with ankylosing spondylitis | |
dc.type | Article | |
dspace.entity.type | Publication | |
relation.isAuthorOfPublication | 1613225c-2f43-4052-9f82-210c854edcf4 | |
relation.isAuthorOfPublication.latestForDiscovery | 1613225c-2f43-4052-9f82-210c854edcf4 |
Files
Original bundle
1 - 1 of 1